文献速递糖尿病

VEGF-A抑制剂sFLT-1通过减少内皮活化和炎症改善1型糖尿病小鼠模型肾功能

The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes.
PubMed 文献 · Diabetologia · 2017-06-15

本研究在1型糖尿病小鼠模型中探讨转染VEGF-A抑制剂sFlt-1能否逆转已存在的肾损伤。结果显示sFlt-1转染显著减少白蛋白尿、肾小球肥大和系膜基质含量,并降低内皮活化、肾小球巨噬细胞浸润及TNF-α水平,提示sFLT-1可能通过抑制VEGF-A减轻内皮活化和肾小球炎症,从而逆转肾损伤。

要点

  • sFlt-1转染显著减少糖尿病小鼠白蛋白尿、肾小球肥大和系膜基质含量(p<0.001)。
  • sFlt-1转染降低内皮活化、肾小球巨噬细胞浸润和肾小球TNF-α蛋白水平(p<0.001)。
  • sFLT-1在体外减少VEGF-A诱导的内皮活化(p<0.001)。

核心结论

  • 这些结果提示sFLT-1可能通过抑制VEGF-A、减少内皮活化和肾小球炎症,最终逆转肾损伤,从而有利于治疗糖尿病肾病。

研究设计与样本

  • 研究使用8周龄雌性C57BL/6J对照小鼠和糖尿病小鼠,糖尿病由三次腹腔注射链脲佐菌素(75 mg/kg,间隔2天)诱导。
  • 未治疗对照小鼠(n=5)和糖尿病小鼠(n=7)在实验开始后5周处死以确定sFLT-1治疗前肾损伤程度。
  • 转染sFlt-1的糖尿病小鼠(n=6)、未转染非糖尿病对照小鼠(n=5)、转染sFlt-1的非糖尿病对照小鼠(n=10)和未转染糖尿病小鼠(n=6)在第15周末处死。
  • sFlt-1转染在第6周进行。

主要发现

  • sFlt-1转染通过使白蛋白尿、肾小球肥大和系膜基质含量(即肾小球IV型胶原蛋白水平)正常化,显著减少肾损伤(p<0.001)。
  • sFlt-1转染减少内皮活化(p<0.001)、肾小球巨噬细胞浸润(p<0.001)和肾小球TNF-α蛋白水平(p<0.001)。
  • sFLT-1在体外减少VEGF-A诱导的内皮活化(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Animal models of diabetic nephropathy show increased levels of glomerular vascular endothelial growth factor (VEGF)-A, and several studies have shown that inhibiting VEGF-A in animal models of diabetes can prevent albuminuria and glomerular hypertrophy. However, in those studies, treatment was initiated before the onset of kidney damage. Therefore, the aim of this study was to investigate whether transfecting mice with the VEGF-A inhibitor sFlt-1 (encoding soluble fms-related tyrosine kinase 1) can reverse pre-existing kidney damage in a mouse model of type 1 diabetes. In addition, we investigated whether transfection with sFlt-1 can reduce endothelial activation and inflammation in these mice. METHODS: Subgroups of untreated 8-week-old female C57BL/6J control (n = 5) and diabetic mice (n = 7) were euthanised 5 weeks after the start of the experiment in order to determine the degree of kidney damage prior to treatment with sFLT-1. Diabetes was induced with three i.p. injections of streptozotocin (75 mg/kg) administered at 2 day intervals. Diabetic nephropathy was then investigated in diabetic mice transfected with sFlt-1 (n = 6); non-diabetic, non-transfected control mice (n = 5); non-diabetic control mice transfected with sFlt-1(n = 10); and non-transfected diabetic mice (n = 6). These mice were euthanised at the end of week 15. Transfection with sFlt-1 was performed in week 6. RESULTS: We found that transfection with sFlt-1 significantly reduced kidney damage by normalising albuminuria, glomerular hypertrophy and mesangial matrix content (i.e. glomerular collagen type IV protein levels) (p < 0.001). We also found that transfection with sFlt-1 reduced endothelial activation (p < 0.001), glomerular macrophage infiltration (p < 0.001) and glomerular TNF-α protein levels (p < 0.001). Finally, sFLT-1 decreased VEGF-A-induced endothelial activation in vitro (p < 0.001). CONCLUSIONS/INTERPRETATION: These results suggest that sFLT-1 might be beneficial in treating diabetic nephropathy by inhibiting VEGF-A, thereby reducing endothelial activation and glomerular inflammation, and ultimately reversing kidney damage.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Bus P, Scharpfenecker M, Van Der Wilk P, et al. The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes. Diabetologia. 2017. PMID: 28620823. doi:10.1007/s00125-017-4322-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。